Datasheet

B-raf Antibody
CATALOG NUMBER: 5777

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Chicken: (93%)
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:B-raf antibody can be used for detection of B-raf by Western blot at 1 - 2 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1303 - Human Brain Tissue Lysate
IMMUNOGEN:B-raf antibody was raised against an 18 amino acid synthetic peptide near the center of human B-raf.

The immunogen is located within amino acids 330 - 380 of B-raf.
HOST SPECIES:Chicken

Properties

PURIFICATION:B-raf Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:B-raf Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:B-raf antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgY
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:B-raf Antibody: NS7, BRAF1, RAFB1, B-RAF1, Proto-oncogene B-Raf
ACCESSION NO.:P15056
PROTEIN GI NO.:50403720
OFFICIAL SYMBOL:BRAF
GENE ID:673

Background

BACKGROUND:B-raf Antibody: B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. Mutations in B-raf have been associated with several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung, leading to speculation on the possibility of B-raf as a therapeutic target for treating cancers. Mutations in this gene have also been associated with cardiofaciocutaneous syndrome (CFCS), a disease characterized by heart defects, mental retardation and a distinctive facial appearance.
REFERENCES: 1) McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta2007; 1773:1263-84.
2) Madhunapantula SV and Robertson GP. Is B-raf a good therapeutic target for melanoma and other malignancies? Cancer Res.2008; 68:5-8.
3) Sarkozy A, Carta C, Moretti S, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum. Mutat.2009; 30:695-702.

For Research Use Only